RegenXBio Posts Updated Data From Hunter Syndrome Gene Therapy Trial
Regenxbio Inc (NASDAQ: RGNX) announced
REGENXBIO Presents Interim Data from Phase I/II Trial Of RGX-121 For Treatment Of MPS II (Hunter Syndrome) At 18th Annual WORLDSymposium 2022
REGENXBIO Inc. (NASDAQ:RGNX) today announced additional positive interim data from Cohorts 1-3 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish.
Regenxbio Highlights Upcoming Presentations At Angiogenesis, Exudation, Degeneration 2022 Conference On Feb. 12 Between 9:10 a.m. And 12:20 p.m. EST
REGENXBIO Inc. (NASDAQ:RGNX) today announced that three oral presentations, including updated interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy, will
SVB Leerink Maintains Market Perform on Regenxbio, Lowers Price Target to $35
SVB Leerink analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Market Perform and lowers the price target from $43 to $35.
Wedbush Initiates Coverage On Regenxbio with Neutral Rating, Announces Price Target of $29
Wedbush analyst Andreas Argyrides initiates coverage on Regenxbio (NASDAQ:RGNX) with a Neutral rating and announces Price Target of $29.
REGENXBIO Presents Additional Interim Data From Trials Of RGX-314 In Wet AMD And Diabetic Retinopathy Using Suprachoroidal Delivery At AAO 2021
REGENXBIO Inc. (NASDAQ:RGNX) today announced additional positive interim data from the ongoing Phase II AAVIATE® trial and the ongoing Phase II ALTITUDE™ trial of RGX-314 using in-office suprachoroidal
Regenxbio Muscular Dystrophy Treatment Gets Orphan Drug Designation
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=847521
Barron’s Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More
This weekend's Barron's cover story examines the bubbles in cryptocurrency, meme stocks and non-fungible tokens.
Other featured articles discuss the stocks powering 2021's top dividend mutual funds and what comes next now that the pandemic trade is over.